<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2023.1259246</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Hepatic stellate cell-intrinsic role of SOCS1 in controlling hepatic fibrogenic response and the pro-inflammatory macrophage compartment during liver fibrosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kandhi</surname>
<given-names>Rajani</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yeganeh</surname>
<given-names>Mehdi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yoshimura</surname>
<given-names>Akihiko</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/22569"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Menendez</surname>
<given-names>Alfredo</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ramanathan</surname>
<given-names>Sheela</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ilangumaran</surname>
<given-names>Subburaj</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<xref ref-type="author-notes" rid="fn004">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/418414"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Universit&#xe9; de Sherbrooke</institution>, <addr-line>Sherbrooke, QC</addr-line>, <country>Canada</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Microbiology and Immunology, Keio University School of Medicine</institution>, <addr-line>Tokyo</addr-line>, <country>Japan</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Universit&#xe9; de Sherbrooke</institution>, <addr-line>Sherbrooke, QC</addr-line>, <country>Canada</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Jagadeesh Bayry, Indian Institute of Technology Palakkad, India</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Jingwei Mao, Dalian Medical University, China; Jaswinder Singh Maras, The Institute of Liver and Biliary Sciences (ILBS), India</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Subburaj Ilangumaran, <email xlink:href="mailto:Subburaj.Ilangumaran@Usherbrooke.ca">Subburaj.Ilangumaran@Usherbrooke.ca</email>
</p>
</fn>
<fn fn-type="other" id="fn004">
<p>&#x2020;ORCID: Subburaj Ilangumaran, <uri xlink:href="https://orcid.org/0000-0002-7563-576X">orcid.org/0000-0002-7563-576X</uri>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>10</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1259246</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>09</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Kandhi, Yeganeh, Yoshimura, Menendez, Ramanathan and Ilangumaran</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Kandhi, Yeganeh, Yoshimura, Menendez, Ramanathan and Ilangumaran</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>Hepatic stellate cells (HSC) become activated, differentiate to myofibroblasts and produce extracellular fibrillar matrix during liver fibrosis. The hepatic fibrogenic response is orchestrated by reciprocal interactions between HSCs and macrophages and their secreted products. SOCS1 can regulate several cytokines and growth factors implicated in liver fibrosis. Here we investigated the role of SOCS1 in regulating HSC activation.</p>
</sec>
<sec>
<title>Methods</title>
<p>Mice lacking SOCS1 in HSCs (<italic>Socs1<sup>&#x394;HSC</sup>
</italic>) were generated by crossing <italic>Socs1<sup>fl/fl</sup>
</italic> and LratCre mice. Liver fibrosis was induced by carbon tetrachloride and evaluated by Sirius red staining, hydroxyproline content and immunostaining of myofibroblasts. Gene expression of pro-fibrogenic factors, cytokines, growth factors and chemokines were quantified by RT-qPCR. The phenotype and the numbers of intrahepatic leukocyte subsets were studied by flow cytometry. The impact of fibrosis on the development of diethyl nitrosamine-induced hepatocellular carcinoma was evaluated.</p>
</sec>
<sec>
<title>Results</title>
<p>
<italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice developed more severe liver fibrosis than control Socs1fl/fl mice that was characterized by increased collagen deposition and myofibroblast differentiation. <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice showed a significant increase in the expression of smooth muscle actin, collagens, matrix metalloproteases, cytokines, growth factors and chemokines in the liver following fibrosis induction. The fibrotic livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice displayed heightened inflammatory cell infiltration with increased proportion and numbers of Ly6ChiCCR2+ pro-inflammatory macrophages. This macrophage population contained elevated numbers of CCR2+CX3CR1+ cells, suggesting impaired transition towards restorative macrophages. Fibrosis induction following exposure to diethyl nitrosamine resulted in more numerous and larger liver tumor nodules in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice than in <italic>Socs1<sup>fl/fl</sup>
</italic> mice. </p>
</sec>
<sec>
<title>Discussion</title>
<p>Our findings indicate that (i) SOCS1 expression in HSCs is a critical to control liver fibrosis and development of hepatocaellular carcinoma, and (ii) attenuation of HSC activation by SOCS1 regulates pro-inflammatory macrophage recruitment and differentiation during liver fibrosis.</p>
</sec>
</abstract>
<kwd-group>
<kwd>alanine transferase (ALT)</kwd>
<kwd>carbon tetrachloride (CCl<sub>4</sub>)</kwd>
<kwd>extracellular matrix (ECM)</kwd>
<kwd>liver fibrosis (LF)</kwd>
<kwd>matrix metalloproteinase (MMP)</kwd>
<kwd>nanozoomer Digital Pathology (NDP)</kwd>
<kwd>suppressor of cytokine signaling (SOCS)</kwd>
</kwd-group>
<counts>
<fig-count count="7"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="84"/>
<page-count count="15"/>
<word-count count="6765"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Molecular Innate Immunity</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Liver fibrosis is a leading cause of global morbidity and mortality (<xref ref-type="bibr" rid="B1">1</xref>). Liver fibrosis also promotes the development of hepatocellular carcinoma (HCC), a major cause of cancer related mortality (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). Hepatocyte damage caused by viral pathogens, toxic chemicals and metabolites and metabolic overload induce an inflammatory response in the liver to contain and repair the damage (<xref ref-type="bibr" rid="B4">4</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>). Mediators released by stressed and dying hepatocytes and cellular debris activate hepatic stellate cells (HSC) and Kupffer cells to initiate an inflammatory response. Monocyte-derived macrophages and other recruited immune cells dynamically participate in liver inflammation and tissue repair (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). The tissue repair process requires production of extracellular matrix (ECM) components such as collagens by myofibroblasts, which arise mainly from HSCs, to aid hepatocyte proliferation and tissue regeneration. However, the hepatic fibrogenic response can become exaggerated with persistent hepatocyte damage, resulting in chronic inflammation, myofibroblast proliferation, excess ECM production and replacement of the liver parenchyma with fibrous connective tissue. Even though liver fibrosis is reversible at early stages, progressive liver fibrosis can lead to liver cirrhosis and loss of vital hepatic functions. HCC predominantly arises in cirrhotic livers, as compensatory hepatocyte proliferation within the prevailing inflammatory milieu facilitates acquisition of genetic lesions and neoplastic transformation (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). Given the clinical significance of liver fibrosis and HCC, intense efforts are being made to halt the progression of liver fibrosis towards cirrhosis and HCC through greater understanding of the cellular and molecular mediators and the underlying mechanisms (<xref ref-type="bibr" rid="B11">11</xref>&#x2013;<xref ref-type="bibr" rid="B14">14</xref>). Various animal models of experimental liver fibrosis and HCC induction have made immense contributions to this endeavor (<xref ref-type="bibr" rid="B15">15</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>).</p>
<p>HSCs are central players in liver fibrosis development and progression, first as a sensor of mediators released by damaged hepatocytes and activated macrophages, and second as the main source of matrix-producing myofibroblasts (<xref ref-type="bibr" rid="B14">14</xref>). HSCs are situated in the space of Disse in close contact with hepatocytes on one side and endothelial cells and the associated Kupffer cells on the sinusoidal side (<xref ref-type="bibr" rid="B18">18</xref>). In normal livers, HSCs are maintained in a non-proliferative quiescent state and function as the principal cell type for storing retinyl esters as cytoplasmic lipid droplets. Upon activation, HSCs lose these vitamin A droplets and transdifferentiate to contractile myofibroblasts that proliferate, express fibrogenic genes and deposit ECM proteins. The activation state of HSCs is perpetuated by several chemokines, cytokines, growth factors and other soluble mediators produced by stressed hepatocytes, biliary epithelial cells, Kupffer cells, recruited proinflammatory macrophages, liver sinusoidal endothelial cells and platelets, whereas IFN&#x3b3; produced by natural killer (NK) and NKT cells inhibits HSC activation (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B19">19</xref>). Upon cessation of the inflammatory stimuli, pro-resolution macrophages play a crucial role in reversing the fibrotic changes by inhibiting HSC activation and by producing enzymes that clear the fibrillar matrix. Fibrosis resolution also involves clearance of activated HSCs through cellular senescence and apoptosis. Targeting the cytokines, chemokines and growth factors that promote HSC activation is a promising strategy for therapeutic intervention of liver fibrosis (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B20">20</xref>).</p>
<p>Cytokines and growth factors that activate HSCs are mainly regulated by mechanisms that control their signaling (<xref ref-type="bibr" rid="B21">21</xref>). Suppressor of cytokine signaling 1 (SOCS1) is an indispensable regulator of IFN&#x3b3; signaling and can also inhibit signaling by many other cytokines and growth factors (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). SOCS1 is also critical to control the production of inflammatory cytokines and chemokines such as IL-6, TNF&#x3b1; and MCP-1/CCL2 by activated macrophages (<xref ref-type="bibr" rid="B24">24</xref>). Low SOCS1 expression correlates with increased fibrosis in human patients with chronic liver disease, and <italic>Socs1</italic> haplo-insufficient mice display increased susceptibility to fibrosis induction by dimethynitrosamine (<xref ref-type="bibr" rid="B25">25</xref>). We have shown that whole body SOCS1-deficient mice in an IFN&#x3b3;-deficient background are highly susceptible to liver fibrosis induction following carbon tetrachloride (CCl<sub>4</sub>)-induced necro-inflammatory chemical injury (<xref ref-type="bibr" rid="B26">26</xref>). We have also shown that selective ablation of SOCS1 in myeloid cells results in heightened sensitivity to liver fibrosis, indicating a key role of SOCS1 in regulating cytokine responses in macrophages during hepatic fibrogenic response (<xref ref-type="bibr" rid="B27">27</xref>). As macrophages release many cytokines and growth factors that directly impact HSCs during liver fibrosis (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B14">14</xref>), we ablated the <italic>Socs1</italic> gene selectively in HSCs using the Cre recombinase expressed under the promoter of lecithin retinol acyltransferase (LRAT) involved in retinol storage in HSCs (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). In the current study, we show that HSC-specific SOCS1 deletion worsens liver fibrosis via enhancing HSC activation and by promoting the accumulation of proinflammatory macrophages, which suggest that SOCS1 expression in HSCs is crucial to control the reciprocal crosstalk between activated HSCs and macrophages.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="s3_1">
<title>Mouse strains</title>
<p>
<italic>Socs1<sup>fl/fl</sup>
</italic> mice (<xref ref-type="bibr" rid="B30">30</xref>) were backcrossed to C57BL/6 mice obtained from Charles River Laboratories for more than ten generations. <italic>Lrat<sup>Cre</sup>
</italic> mice were obtained from Dr. C. &#xd6;sterreicher (University of Vienna) (<xref ref-type="bibr" rid="B29">29</xref>) and rederived by cesarian section into the specific pathogen-free facility in our animal colony. <italic>R26<sup>ZsGreen</sup>
</italic> reporter mice (Jax mice: 007906; B6. Cg-Gt(ROSA)26Sor tm6(CAG-ZsGreen1) Hze/J; also known as Ai6 mouse) (<xref ref-type="bibr" rid="B31">31</xref>) were obtained from the Jackson Laboratory. The <italic>R26<sup>ZsGreen</sup>
</italic> reporter mouse harbors a targeted mutation at the Rosa 26 locus (Gt (ROSA)26S) with a loxP-flanked STOP cassette, which prevents the transcription of a CAG promoter-driven enhanced green fluorescent protein ZsGreen1. <italic>Lrat<sup>Cre</sup>
</italic> mice were bred with the <italic>R26<sup>ZsGreen</sup>
</italic> reporter to verify <italic>Lrat<sup>Cre</sup>
</italic>-induced ZsGreen expression in HSCs. <italic>Socs1<sup>fl/fl</sup>
</italic> mice were bred with <italic>Lrat<sup>Cre</sup>
</italic> mice to generate <italic>Socs1<sup>fl/fl</sup>Lrat<sup>Cre</sup>
</italic> mice lacking SOCS1 expression in HSCs (<italic>Socs1<sup>&#x394;HSC</sup>
</italic>). Mice were housed in ventilated cages with 12 hours day/night cycle and fed with normal chow <italic>ad libitum</italic>. All experiments on mice were carried out during daytime with the approval of the Universit&#xe9; de Sherbrooke Ethics Committee for Animal Care and Use (Protocol ID: 2018-2083).</p>
</sec>
<sec id="s3_2">
<title>Induction of liver fibrosis</title>
<p>To induce liver fibrosis, carbon tetrachloride (CCl<sub>4</sub>; Sigma-Aldrich, Oakville, ON) diluted at 1:3 ratio in corn oil was administered via intra-peritoneal route (0.5 &#x3bc;L/g body weight) in 8-10-week-old mice twice a week for five weeks (<xref ref-type="bibr" rid="B32">32</xref>). Only male mice were used in this study due to the protective effect of estrogens on inflammatory cytokine production in female mice (<xref ref-type="bibr" rid="B33">33</xref>&#x2013;<xref ref-type="bibr" rid="B35">35</xref>). Three days after the last injection, mice were euthanized, and serum and liver tissues were collected. Liver tissues were processed for histology, protein and mRNA expression and flow cytometry analyses of intrahepatic leukocytes, as detailed below.</p>
</sec>
<sec id="s3_3">
<title>Measurement of serum ALT and liver hydroxyproline content</title>
<p>Serum alanine transferase (ALT) levels were measured using a kinetic assay kit from Pointe Scientific Inc. (Brussels, Belgium) following manufacturer&#x2019;s instructions. Hydroxyproline content in liver tissue homogenates was measured as described previously (<xref ref-type="bibr" rid="B26">26</xref>).</p>
</sec>
<sec id="s3_4">
<title>Histology</title>
<p>Pieces of liver tissues were fixed in 4% paraformaldehyde overnight and stored in 70% ethanol until they were processed for paraffin embedding following standard methods. Sections of formalin-fixed paraffin embedded liver tissues (5 &#xb5;m) were deparaffinized, rehydrated, and stained with hematoxylin and eosin (H&amp;E) or Sirius red as previously described (<xref ref-type="bibr" rid="B26">26</xref>). Digital images of stained sections were acquired using a Nanozoomer Digital Pathology (NDP) slide scanner and analyzed using the NDP.view2 software (Hamamatsu Photonics, Japan). Quantification of Sirius red staining areas was done using the Image J software (National Institutes of Health, Bethesda, MD, USA) from twenty randomly selected fields from three to five mice in each group.</p>
</sec>
<sec id="s3_5">
<title>Immunohistochemistry and immunofluorescence</title>
<p>Immunohistochemical (IHC) staining of liver sections for alpha smooth muscle actin (&#x3b1;SMA) was done as previously described to detect myofibroblasts (<xref ref-type="bibr" rid="B26">26</xref>) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S1</bold>
</xref>). Macrophages were detected by immunofluorescence (IF) staining. Deparaffinized tissue sections were incubated overnight with CD68 antibody (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S1</bold>
</xref>) followed by a AlexaFluor-488-conjugated secondary antibody (Invitrogen/ThermoFisher Scientific) for 1 h at room temperature in the dark. Nuclei were stained with Hoechst 33342 (Thermo Fisher; Cat# 62249) for 5 min at room temperature. The stained slides were washed and mounted in Vectashield (Vector Laboratories; Cat# H-1900) antifading medium. IHC images were captured using the NDP slide scanner and IF images acquired using Axioskop 2 fluorescence microscope (Carl Zeiss Canada Ltd, Toronto, Canada). Staining intensity of &#x3b1;SMA and the proportion of CD68 positive cells were quantified in three randomly selected fields from three to five mice in each group using the NIH ImageJ software.</p>
</sec>
<sec id="s3_6">
<title>Gene expression analysis</title>
<p>RNA extraction, cDNA preparation and gene expression analysis by RT-qPCR were carried out as described previously (<xref ref-type="bibr" rid="B26">26</xref>). All RT-qPCR primers (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S2</bold>
</xref>) showed more than 90% efficiency and displayed a single melting curve. Expression levels of specific genes were normalized for the housekeeping gene <italic>Rplp0</italic> (36B4) within each experimental group and expressed as fold induction compared to the control group.</p>
</sec>
<sec id="s3_7">
<title>Western blot</title>
<p>Liver tissue lystaes were prepared from snap frozen samples using a tissue homogenizer bead mill (MM 400; Retsch, Hann, Germany) and protein concentration determined as previously described (<xref ref-type="bibr" rid="B26">26</xref>). Thirty &#x3bc;g of total protein from each sample were separated on SDS-polyacrylamide gels, blotted on to PVDF membrane and probed for the indicated proteins using the primary antibodies listed in <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S3</bold>
</xref>. HRP-conjugated mouse and rabbit secondary antibodies and enhanced chemiluminescence reagents (GE Healthcare Life Sciences, Pittsburg, PA) were used to reveal the western blot bands. Images were captured using the VersaDOC 5000 imaging system (Bio-Rad).</p>
</sec>
<sec id="s3_8">
<title>Primary HSC isolation, culture and activation</title>
<p>HSCs were isolated from 12-weeks old mice by equilibrium density gradient centrifugation of liver cells released by collagenase digestion, following published methods with some modifications (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). Mice were anesthetized by intraperitoneal administration of Ketamine-Xylazine mixture (Ketamine-87 mg/kg; Xylazine-13 mg/kg - in normal saline), placed on supine position, the liver was exposed and the inferior vena cava canulated as described by Mederacke et&#xa0;al. (<xref ref-type="bibr" rid="B37">37</xref>). The livers were perfused with 0.5 mM EGTA in HEPES-buffered Hank&#x2019;s balanced salt solution (HHBSS: NaCl 140 mM, KCl 5.4 mM, Na<sub>2</sub>HPO<sub>4</sub> 0.34 mM, NaHCO<sub>3</sub> 4.2 mM, KH<sub>2</sub>PO<sub>4</sub> 0.44 mM; MgCl<sub>2</sub> 0.4 mM, HEPES 10 mM, D-glucose 100 mg/L) without calcium, maintained at 42&#xb0;C in a water bath, for 2 min using a peristaltic pump, with the portal vein severed to flush out erythrocytes. The liver parenchyma was digested by perfusion with freshly prepared Type IV collagenase (Worthington Biochemical; Cat # LS004186; 18 mg of 325 collagen digestion units) in 50 mL of prewarmed HHBSS containing 1.5 mM CaCl<sub>2</sub> (wash buffer). Tissue digestion was stopped when the liver became amorphous and collapsed (~7 min). The digested liver was carefully removed and aseptically transferred to a Petri dish. The liver tissue was teased apart using forceps to release cells into suspension, which was passed through 70 &#x3bc;m nylon filter strainer (BD Falcon) to remove tissue debris. Hepatocytes were sedimented by centrifuging the cell suspension at 50 g for 5 min at 4&#xb0;C. Nonparenchymal cells were pelleted down by centrifuging the supernatant at 500 g for 10 min at 4&#xb0;C. The cell pellet was resuspended in 5 mL 20% OptiPrep&#x2122; (Axis Shield; 60% stock diluted with wash buffer), transferred to a 15 mL tube, slowly overlaid with 5 mL 11.5% OptiPrep and then 2 mL wash buffer, and centrifuged at 1500 g for 17 min at 4&#xb0;C without brake. An opaque layer formed at the interface between 11.5% OptiPrep and the wash buffer was carefully collected with a Pasteur pipette and the cells were washed at 500 g for 5 min at 4&#xb0;C. The cells were resuspended in DMEM containing 10% FCS and counted.</p>
<p>For IF microscopy, HSCs were seeded on coverslips in a 12 well plate at 1 &#xd7;10<sup>5</sup> cells/well in DMEM-10% FCS and cultured with the indicated cytokines and growth factors. Control and stimulated cells on coverslips were washed in phosphate-buffered saline (PBS), fixed in ice-cold methanol for 5 min at room temperature, followed by washing in PBS three times each for 5 min. The coverslips were incubated in PBST (PBS with 0.2% Triton X-100) containing 5% BSA for 1 h to block non-specific Ab binding. This was followed by incubation with primary Ab diluted in PBST-1% BSA in a humidified chamber for 1 h at room temperature or overnight at 4&#xb0;C. Subsequent steps were similar to those described for IF microscopy of tissue sections.</p>
<p>For gene expression studies, control HSCs were lysed immediately after isolation in RNAlater (ThermoFisher Scientific). For stimulation with cytokines and growth factors, primary HSCs were cultured in 35 mm Petri dishes (0.5 &#xd7;10<sup>6</sup> cells/well) and cultured in DMEM-10% FCS in the presence of IL-6 (10 ng/mL), TGF&#x3b2; (5 ng/mL) or PDGFB (20 ng/mL) (all from R&amp;D Sytems, Minniapolis, MN). After for 24 h incubation, the cells were lysed in RNAlater for gene expression analysis as previously described (<xref ref-type="bibr" rid="B26">26</xref>).</p>
</sec>
<sec id="s3_9">
<title>Isolation of intrahepatic leukocytes and flow cytometry</title>
<p>IHLs were isolated by a four steps protocol involving (i) controlled collagenase digestion of minced liver tissue using the GentleMACS tissue dissociator device (Miltenyi Biotech), (ii) microfiltration and sedimentation of hepatocytes and IHLs by differential centrifugation, (iii) Percoll gradient centrifugation of sedimented IHLs to remove fatty debris, and (iv) magnetic selection of hematopoietic cells using anti-CD45 antibody to clarify the resuspended Percoll-sedimented cells as detailed elsewhere (<xref ref-type="bibr" rid="B38">38</xref>). This IHL isolation procedure developed for fatty liver tissues is applicable to fibrotic and normal livers. The cells were resuspended in PBS containing 2% fetal bovine serum (FBS) for flow cytometry analysis.</p>
<p>Aliquots of IHLs were incubated in 100 &#x3bc;L of Fc Block diluted in PBS-2%FBS for 10 min on ice. After washing in PBS-2%FBS, the cells are incubated with a panel of fluorochrome conjugated antibodies (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S4</bold>
</xref>) diluted in PBS-2%FBS. The cells were washed and fluorescence data were acquired using the CytoFlex flow cytometer (Beckman Coulter). The data was analyzed using the FlowJo software (BD Biosciences).</p>
</sec>
<sec id="s3_10">
<title>Induction of HCC</title>
<p>To induce HCC, 2 weeks old male mice were injected via intra peritoneal route diethylnitrosamine (DEN; Millipore-Sigma; 25 mg/Kg body weight) followed by bi-weekly injections of CCl<sub>4</sub> (0.5 ml/Kg) starting at 8 weeks of age for 14 consecutive weeks (<xref ref-type="bibr" rid="B39">39</xref>). Mice were euthanized after 22 weeks and tumor development assessed by counting the number of nodules and measuring the liver/body weight ratio.</p>
</sec>
<sec id="s3_11">
<title>Statistical analyses</title>
<p>The data were compiled on an Excel spreadsheet (Microsoft 365) and Prism V9.3.1 software (GraphPad, La Jolla, CA, USA) was used to plot graphs and for statistical analysis. <italic>p</italic> values &lt;0.05 were considered significant.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s4_1">
<title>SOCS1 loss in HSCs exacerbates chemically induced liver fibrosis</title>
<p>Cytokines and growth factors produced by stressed hepatocytes and activated macrophages are the key drivers of liver fibrosis and represent potential therapeutic targets (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B12">12</xref>). The loss of SOCS1, a key regulator of inflammatory cytokine and growth factor signaling in the liver, promotes liver fibrosis (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B40">40</xref>). Primary HSCs isolated from SOCS1-deficient mice display increased proliferation in response to IL-6, PDGF, EGF, TGF&#x3b1; and HGF, suggesting a cell-intrinsic role of SOCS1 in regulating HSC activation (<xref ref-type="bibr" rid="B26">26</xref>). To directly assess the role of SOCS1 in regulating HSCs responses during liver fibrosis, we crossed <italic>Socs1<sup>fl/fl</sup>
</italic> mice with <italic>Lrat<sup>Cre</sup>
</italic> deleter mice, which ablates floxed genes specifically in HSCs in the liver (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). We confirmed the expression of <italic>Lrat</italic> promoter driven Cre expression in HSCs using the ROSA26-ZsGreen reporter mice (<xref ref-type="bibr" rid="B31">31</xref>). Cryosections of livers from <italic>Lrat<sup>Cre</sup>
</italic>ROSA26-ZsGreen mice showed a ZsGreen expression pattern that is consistent with the distribution of HSCs (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1A</bold>
</xref>), which was confirmed by immunostaining for the HSC marker desmin (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1B</bold>
</xref>) as well as by verifying ZsGreen expression in primary HSCs (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1C-E</bold>
</xref>).</p>
<p>Liver fibrosis was induced in <italic>Socs1<sup>&#x394;HSC</sup> and Socs1<sup>fl/fl</sup>
</italic> control mice by intraperitoneal administration of CCl<sub>4</sub> twice a week for 5 weeks. Sirius red staining of the liver sections of these mice showed increased collagen deposition with prominent bridging fibrosis pattern compared to limited septal fibrosis observed in <italic>Socs1<sup>fl/fl</sup>
</italic> control mice (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). Quantification of the staining area and intensity showed significantly elevated levels of collagen deposition in HSC-specific SOCS1-deficient mice livers that was confirmed by hepatic hydroxyproline content (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B, C</bold>
</xref>), Masson&#x2019;s trichrome staining and western blot (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S2</bold>
</xref> and <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>). However, the increase in serum ALT levels following CCl<sub>4</sub> treatment was comparable between <italic>Socs1<sup>&#x394;HSC</sup>
</italic> and <italic>Socs1<sup>fl/fl</sup>
</italic> control mice (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>), suggesting that increased fibrosis in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice resulted from increased fibrogenic response caused by the loss of SOCS1 in HSCs rather than from increased liver damage. This was confirmed by immunohistochemical staining of &#x3b1;SMA in myofibroblasts, which showed intense staining and significantly increased staining area in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice compared to <italic>Socs1<sup>fl/fl</sup>
</italic> controls (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1F, G</bold>
</xref>). Consistent with this data, CCl<sub>4</sub>-treated <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice livers showed increased expression of <italic>Acta2</italic> and <italic>Col1a1</italic> genes and &#x3b1;SMA and collagen 1 protein expression (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1H, D</bold>
</xref>). The fibrotic livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice showed significantly elevated expression of <italic>Col3a1</italic>, the antifibrotic matrix metalloproteinase 2 (<italic>Mmp2</italic>) (<xref ref-type="bibr" rid="B41">41</xref>) and tissue inhibitor of MMPs 1 (<italic>Timp1</italic>) genes compared to <italic>Socs1<sup>fl/fl</sup>
</italic> mice livers (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1H</bold>
</xref>). Moreover, expression of genes coding for proinflammatory cytokines IL-6 and IL-1&#x3b2;, profibrogenic TGF&#x3b2; and the myofibroblast growth factor PDGFB, which were markedly induced in <italic>Socs1<sup>fl/fl</sup>
</italic> mice livers, was significantly elevated in the fibrotic livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1I</bold>
</xref>). These data indicated that SOCS1 expression in HSCs plays a crucial role in regulating hepatic fibrogenic response induced by chemical agents.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>SOCS1 deficiency in HSCs increases the severity of liver fibrosis induced by CCl<sub>4</sub>. Eight weeks old male <italic>Socs1<sup>&#x394;HSC</sup>
</italic> and sex matched <italic>Socs1<sup>fl/fl</sup>
</italic> littermate controls were treated with CCl<sub>4</sub> or vehicle (corn oil) twice a week for five weeks and euthanized three days later. <bold>(A)</bold> Sirius red staining for collagen deposition. Representative data from at least three mice for each group are shown. <bold>(B)</bold> Quantification of sirius red staining areas. Mean &#xb1; standard error of mean (SE) from three to six mice per group for two independent experiments. <bold>(C)</bold> Hydroxy proline content of liver tissues. Mean &#xb1; SE from five to eight mice per group from two experiments. <bold>(D)</bold> Western blot evaluation of collagen 1 and &#x3b1;SMA proteins in the liver tissues from three mice in each group. Beta actin was used as a loading control. <bold>(E)</bold> Serum ALT levels from four mice per group from two different experiments are shown (mean &#xb1; SE). <bold>(F)</bold> IHC staining of &#x3b1;SMA in representative liver sections. Representative data from at least three mice in each group are shown. <bold>(G)</bold> Quantification of &#x3b1;SMA staining area. Mean &#xb1; SE from three to five mice per group from two experiments. <bold>(H, I)</bold> RT-qPCR evaluation of the expression of genes associated with hepatic fibrogenic response <bold>(H)</bold>, cytokines and growth factors <bold>(I)</bold>. n = 6-8 mice per group from a minimum of two separate experiments. Statistical significance was assessed by one-way ANOVA with Tukey&#x2019;s multiple comparison test. ns, not significant; * <italic>p &lt;</italic>0.05, ** <italic>p &lt;</italic>0.01, *** <italic>p &lt;</italic>0.001; **** <italic>p &lt;</italic>0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1259246-g001.tif"/>
</fig>
</sec>
<sec id="s4_2">
<title>SOCS1-deficient HSCs display increased responsiveness to TGF&#x3b2; stimulation</title>
<p>As TGF&#x3b2; is a key driver of ECM deposition (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>), we examined TGF&#x3b2; signaling pathway components in the fibrotic livers of <italic>Socs1<sup>&#x394;HSC</sup> and Socs1<sup>fl/fl</sup>
</italic> mice. <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice displayed increased phosphorylation of SMAD2 and SMAD3 in both CCl<sub>4</sub> and oil treated groups (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). On the other hand, increased SMAD3 phosphorylation was observed in the livers of <italic>Socs1<sup>fl/fl</sup>
</italic> mice only after CCl<sub>4</sub> treatment, whereas SMAD2 phosphorylation level was not altered (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). Similarly, phosphorylation of the MAP kinase ERK1/2 was prominent in both in both CCl<sub>4</sub> and oil treated groups of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice but occurred only after CCl<sub>4</sub> treatment in control mice (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). These observations suggested increased responsiveness of SOCS1-deficient HSCs to TGF&#x3b2; and growth factor signaling that promoted their fibrogenic response. To test this possibility, primary HSCs enriched from <italic>Socs1<sup>&#x394;HSC</sup>
</italic> and <italic>Socs1<sup>fl/fl</sup>
</italic> mice were exposed to inflammatory (IL-6), fibrogenic (TGF&#x3b2;) and growth stimulating (PDGFB) cytokines and the induction genes that promote myofibroblast differentiation (<italic>Acta2</italic>) and matrix production (<italic>Col1a1</italic>) and remodelling (<italic>Mmp2</italic>, <italic>Timp1</italic>) was evaluated. TGF&#x3b2; strongly induced <italic>Acta2</italic>, <italic>Col1a1</italic>, <italic>Mmp2</italic> and <italic>Timp1</italic> genes in control HSCs and the induction of all but <italic>Mmp2</italic> were further amplified significantly by SOCS1 deficiency (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>). Whereas IL-6 caused a discernible increase in the expression of <italic>Acta2</italic>, <italic>Col1a1</italic> and <italic>Mmp2</italic> genes in control and SOCS1-deficient HSCs, PDGFB, the most potent growth factor for HSCs (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B44">44</xref>), did not change the expression of these fibrogenic genes. Notably, SOCS1-deficient HSCs showed discernibly elevated basal expression of <italic>Acta2</italic> and <italic>Timp1</italic> genes (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>), suggesting production of autocrine fibrogenic mediators in SOCS1-deficient HSCs. Indeed, TGF&#x3b2; stimulation upregulated <italic>Tgfb</italic> and <italic>Pdgfb</italic> genes in control HSCs that was significantly amplified by SOCS1 deficiency (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>). Immunofluorescence staining of &#x3b1;SMA following TGF&#x3b2; stimulation showed profound increase in SOCS1-deficient HSCs compared to control HSCs (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>). These results indicated that SOCS1 is a critical to regulator of HSC activation by limiting their responsiveness to TGF&#x3b2; stimulation and TGF&#x3b2;-induced autocrine mediator production.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Primary HSCs from <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice show increased responsiveness to TGF&#x3b2; stimulation. <bold>(A)</bold> Phosphorylated and total SMAD2, SMAD3 and ERK1/2 protein levels in the liver tissues from three mice in the indicated groups. <bold>(B)</bold> RT-qPCR evaluation of the expression of genes associated with hepatic fibrogenic response following stimulation with IL-6 (10 ng/mL), TGF&#x3b2; (5 ng/mL) or PDGFB (20 ng/mL) for 24 h. Mean &#xb1; SE of data was pooled from in triplicate cultures from two experiments were compared by one-way ANOVA with Tukey&#x2019;s multiple comparison test. * <italic>p &lt;</italic>0.05, ** <italic>p &lt;</italic>0.01, *** <italic>p &lt;</italic>0.001; **** <italic>p &lt;</italic>0.0001. ns, not significant. <bold>(C)</bold> IF evaluation of &#x3b1;SMA expression in four days old primary HSC cultures from <italic>Socs1<sup>fl/fl</sup>
</italic> and <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice without or with TGF&#x3b2; stimulation (5 ng/mL) for 24 h. Representative images from two experiments are shown.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1259246-g002.tif"/>
</fig>
</sec>
<sec id="s4_3">
<title>SOCS1 expression in HSCs regulates inflammatory cell recruitment during liver fibrosis</title>
<p>Hematoxylin and eosin-stained liver sections of CCl<sub>4</sub>-treated mice revealed increased inflammatory cell infiltration in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice in the periportal area and around the central vein compared to <italic>Socs1<sup>fl/fl</sup>
</italic> controls (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). This observation suggested that SOCS1 deficiency in HSCs enhances hepatic inflammatory response during fibrogenesis. In support of this notion, the expression of the <italic>Ccl2</italic> chemokine gene, which is strongly induced by CCL<sub>4</sub> treatment in control mice, was further increased in HSC-specific SOCS1-deficient mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>). However, the induction of <italic>Ccl5</italic> (RANTES) and <italic>Cx3cl1</italic> (Fractalkine) genes was comparable between <italic>Socs1<sup>&#x394;HSC</sup>
</italic> and <italic>Socs1<sup>fl/fl</sup>
</italic> mice livers. We also observed that TGF&#x3b2; strongly induced the <italic>Ccl2</italic> gene in primary HSCs that was significantly elevated in SOCS1-deficient HSCs (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>). As <italic>Ccl2</italic> encodes the macrophage chemoattractant protein 1 (MCP1/CCL2), we examined the distribution of macrophages in the CCL<sub>4</sub>-treated livers. The fibrotic livers of <italic>Socs1<sup>fl/fl</sup>
</italic> mice harbored significantly more CD68+ cells, possibly representing Kupffer cells arising from recruited macrophages (<xref ref-type="bibr" rid="B45">45</xref>), and their numbers increased further in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice compared to <italic>Socs1<sup>fl/fl</sup>
</italic> mice (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C, D</bold>
</xref>). Flow cytometry analysis of intrahepatic leukocytes revealed that the proportion and number of total CD45+CD11b+ myeloid cells and CD11b+Ly6G+ polymorphonuclear neutrophils, which were comparable between vehicle-treated <italic>Socs1<sup>&#x394;HSC</sup>
</italic> and <italic>Socs1<sup>fl/fl</sup>
</italic> mice, significantly increased following fibrosis induction and this increase was further augmented by SOCS1 deficiency in HSCs (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3E&#x2013;G</bold>
</xref>). These data indicated that SOCS1 expression in HSCs is crucial to control immune cell recruitment and to regulate fibrosis-associated inflammatory response during liver fibrosis.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Fibrotic livers of HSC-specific SOCS1 deficient mice show increased innate immune cell infiltration. <bold>(A)</bold> Representative hematoxylin and eosin-stained liver sections of <italic>Socs1<sup>fl/fl</sup>
</italic> and <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice treated with corn oil or CCl<sub>4</sub> at lower (left panels) and higher (right panels) magnification. <bold>(B)</bold> RT-qPCR evaluation of chemokine gene expression in liver tissues. Mean &#xb1; SE from 6-8 mice per group from at least two separate experiments <bold>(C)</bold> CD68 IF staining of representative liver sections. Insets show magnified images for CCl<sub>4</sub>-treated mice livers. <bold>(D)</bold> Quantification of CD68+ cells. Mean &#xb1; SE quantified from 8-10 fields from 3-4 mice/group. <bold>(E)</bold> Immunophenotyping of IHLs from corn oil or CCl<sub>4</sub> treated mice groups by flow cytometry. Representative zebra blots showing distribution of CD45+, CD45+CD11b+ and CD45+CD11b+Ly6G+ cells. Numbers inside the plots indicate the proportion of cells within the gated cell populations. <bold>(F, G)</bold> Proportions and absolute counts of CD45+CD11b+ myeloid cells <bold>(F)</bold> and CD45+CD11b+Ly6G+ polymorphonuclear cells <bold>(G)</bold> in the indicated groups of mice. Pooled data from 5-7 mice per group from two different experiments are shown (mean &#xb1; SE). One-way ANOVA with Tukey&#x2019;s multiple comparison test. * <italic>p &lt;</italic>0.05, ** <italic>p &lt;</italic>0.01, *** <italic>p &lt;</italic>0.001; **** <italic>p &lt;</italic>0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1259246-g003.tif"/>
</fig>
</sec>
<sec id="s4_4">
<title>SOCS1 loss in HSCs promotes a pro-inflammatory macrophage phenotype</title>
<p>The increased numbers of myeloid cells (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3E, F</bold>
</xref>) and the heightened induction of <italic>Il6</italic>, <italic>Il1b</italic>, <italic>Tgfb</italic> and <italic>Pdgfb</italic> genes in CCl<sub>4</sub>-treated livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1I</bold>
</xref>), suggested potent activation of monocyte-derived macrophages. To test this hypothesis, we evaluated the expression level of proinflammatory macrophage marker Ly6C (<xref ref-type="bibr" rid="B45">45</xref>) on CD45+CD11b+ cells (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>). The fibrotic livers of <italic>Socs1<sup>fl/fl</sup>
</italic> mice livers harbored increased proportion and number of Ly6C<sup>hi</sup> proinflammatory macrophages that were further increased in the livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>). Even though Ly6C<sup>lo</sup> anti-inflammatory macrophages were significantly reduced in frequency in the fibrotic livers of both <italic>Socs1<sup>fl/fl</sup>
</italic> and <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice, absolute number of this macrophage subset was not significantly altered (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4C</bold>
</xref>). Proinflammatory macrophages are also characterized by the upregulation the chemokine receptor CCR2 (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>). When the expression of CCR2 and Ly6C was examined on CD11b+Ly6G- cells, we observed a significant increase in the proportion and number of Ly6C<sup>hi</sup>CCR2+ cells in CCl<sub>4</sub>-treated livers of <italic>Socs1<sup>fl/fl</sup>
</italic> mice that was further increased in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4D, E</bold>
</xref>). The proportion of Ly6C<sup>hi</sup> cells that did not express CCR2 significantly decreased in both <italic>Socs1<sup>fl/fl</sup>
</italic> and <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice, although their absolute numbers of were not significantly affected (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4F</bold>
</xref>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Increased inflammatory macrophage infiltration in the fibrotic livers of HSC-specific SOCS1 deficient mice. <bold>(A)</bold> Representative density blots showing expression of the proinflammatory monocyte marker Ly6C within the CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G&#x2212; cells in the livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> and <italic>Socs1<sup>fl/fl</sup>
</italic> control mice. Gates represented by alphabets identify (a) Ly6C&#x2212; (b) Ly6C<sup>lo</sup> and (c) Ly6C<sup>hi</sup> macrophage populations, and the numbers indicate their proportions within the gates. <bold>(B, C)</bold> Proportions and absolute counts of Ly6G&#x2212;Ly6C<sup>hi</sup> proinflammatory macrophages compared to the Ly6G&#x2212;Ly6C<sup>lo</sup> subset. <bold>(D)</bold> Representative zebra blots showing expression of the proinflammatory macrophage marker CCR2 within the CD45+CD11b+Ly6G&#x2212;Ly6C<sup>hi</sup> macrophage population in the livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> and <italic>Socs1<sup>fl/fl</sup>
</italic> control mice. Gates represented by alphabets identify (d) CCR2+ and (e) CCR2&#x2212; cell populations, and the numbers indicate their proportions within the gates. <bold>(E, F)</bold> Proportions and absolute counts of Ly6C<sup>hi</sup>CCR2+ and Ly6C<sup>hi</sup>CCR2&#x2212; subsets. Mean &#xb1; SE data was pooled from 5-7 mice per group from two different experiments and compared by one-way ANOVA with Tukey&#x2019;s multiple comparison test. * <italic>p &lt;</italic>0.05, ** <italic>p &lt;</italic>0.01, *** <italic>p &lt;</italic>0.001; **** <italic>p &lt;</italic>0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1259246-g004.tif"/>
</fig>
</sec>
<sec id="s4_5">
<title>CCR2+CX3CR1+ macrophages accumulate in the fibrotic livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice</title>
<p>During fibrosis progression proinflammatory macrophages transition to restorative macrophages that promote tissue repair and fibrosis resolution after cessation of the inflammatory stimuli (<xref ref-type="bibr" rid="B45">45</xref>). The pro-resolution macrophages are characterized by the expression of the CX3CR1 chemokine receptor. Segregation of the macrophage population based on the expression of Ly6C and CX3CR1 revealed that the proportion of Ly6C<sup>lo</sup>CX3CR1+ pro-resolution macrophages did not change in the livers of CCl<sub>4</sub>-treated <italic>Socs1<sup>fl/fl</sup>
</italic> and <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice although their numbers showed a discernible, though not significant, increase in both groups (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A, B</bold>
</xref>
<bold>)</bold>. On the other hand, the proportion and number of Ly6C<sup>hi</sup> cells that also expressed CX3CR1 was markedly upregulated in the fibrotic livers of <italic>Socs1<sup>fl/fl</sup>
</italic> and <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice, with a significant increase in both frequency and number (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A, C</bold>
</xref>
<bold>)</bold>. Next, we analyzed the co-expression of CCR2 and CX3CR1 within CD11b+Ly6G&#x2212;Ly6C<sup>hi</sup> pro-inflammatory macrophage population. We observed a marked increase in the frequency of Ly6C<sup>hi</sup>CCR2+CX3CR1+ cells in both <italic>Socs1<sup>fl/fl</sup>
</italic> and <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice with significantly elevated number of these cells in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5D, E</bold>
</xref>
<bold>)</bold>. These results suggest that the increased inflammatory response in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice prevents these intermediate or transitional macrophages from acquiring the CX3CR1+Ly6C<sup>lo</sup>CCR2&#x2212; restorative macrophage phenotype.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Fibrotic livers of HSC-specific SOCS1 deficient mice accumulate macrophages expressing both CCR2 and CX3CR1. <bold>(A)</bold> Representative zebra blots showing the expression of Ly6C and CX3CR1 within the CD45+CD11b+Ly6G&#x2212; cells in the livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> and <italic>Socs1<sup>fl/fl</sup>
</italic> control mice. Gates represented by alphabets identify (f) Ly6C<sup>lo</sup>CX3CR1+ and (g) Ly6C<sup>hi</sup>CX3CR1+ macrophage populations, and the numbers indicate their proportions within the gates. <bold>(B, C)</bold> Proportions and absolute counts of) Ly6C<sup>lo</sup>CX3CR1+ pro-resolution macrophages compared to the Ly6C+CX3CR1+ proinflammatory subset. <bold>(D)</bold> Representative density blots showing the expression of CCR2 and CX3CR1 within the CD45+CD11b+Ly6C+ cells in the fibrotic livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> and <italic>Socs1<sup>fl/fl</sup>
</italic> control mice. <bold>(E)</bold> Proportions and absolute counts of Ly6C+CCR2+CX3CR1+ macrophages. Pooled data from 4-6 mice per group from two different experiments are shown (mean &#xb1; SEM). One-way ANOVA with Tukey&#x2019;s multiple comparison test. * <italic>p &lt;</italic>0.05, ** <italic>p &lt;</italic>0.01, *** <italic>p &lt;</italic>0.001, **** <italic>p &lt;</italic>0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1259246-g005.tif"/>
</fig>
</sec>
<sec id="s4_6">
<title>SOCS1 deficiency in HSCs promotes enrichment of CD11b+CD11c+ myeloid DCs and CD8+ T cells during liver fibrosis</title>
<p>The fibrotic livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice also contained an increased frequency and number of CD11b+CD11c+ myeloid dendritic cells (DC), whereas the number of plasmacytoid DCs were not affected (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S3</bold>
</xref>). The livers of CCl<sub>4</sub>-treated <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice also harbored an elevated number of CD8+ T lymphocytes that displayed an activated effector (CD69+), effector memory (CD44<sup>hi</sup>CD62L<sup>lo</sup>) and central memory (CD44<sup>hi</sup>CD62L<sup>hi</sup>) phenotype, whereas the numbers of CD4 T and NK cells and the activation status of CD4+ T cells were not affected (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S4, S5</bold>
</xref>).</p>
</sec>
<sec id="s4_7">
<title>Increased liver fibrosis promotes HCC development in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice</title>
<p>Liver fibrosis driven by activated HSC and the associated inflammation driven by macrophages are important drivers of HCC development and progression (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). To determine if increased liver fibrosis in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice promotes HCC development, we administered DEN to 2 weeks old mice followed by CCl<sub>4</sub> treatment beginning at 8 weeks of age and continued for 14 weeks to induce and sustain liver fibrosis (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6A</bold>
</xref>). Examination of the livers at the end of this treatment period revealed increased liver body weight ratio in <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice than in control mice, with increased number of liver tumor nodules that showed histological features of hepatocellular carcinoma (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B&#x2013;D</bold>
</xref>).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>SOCS1 deficiency in HSCs enhances hepatocarcinogenesis in fibrotic livers. <bold>(A)</bold> Schematic representation of hepatocellular carcinoma induction. Two weeks old <italic>Socs1<sup>fl/fl</sup>Lrat<sup>Cre</sup>
</italic> mice (n=8) and <italic>Socs1<sup>fl/fl</sup>
</italic> controls (n=7) were injected with DEN (25 mg/kg BW, i.p.). Six weeks later, the mice were administered CCl<sub>4</sub> (0.5 ml/kg BW, i.p.), weekly for 14 weeks, and euthanized at the age of 22 weeks. <bold>(B)</bold> Representative images of livers showing HCC nodules. <bold>(C)</bold> Liver to body weight ratio and the number of surface liver nodules per mouse. Data shown as Mean &#xb1; SE from 6-7 mice per group were compared by two-tailed unpaired t-test. * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01. <bold>(D)</bold> Representative H&amp;E sections of the tumor bearing livers. T, tumor nodule.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1259246-g006.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Myofibroblasts that differentiate from HSCs are key pathogenic mediators of hepatic fibrosis that can progress towards HCC and thus are considered a key therapeutic target (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B47">47</xref>). Genetic targeting of HSCs has been widely used to gain deeper understanding of the molecular basis of HSC activation, differentiation and fibrogenic functions. These efforts to track HSCs or modulate their gene expression have employed mice expressing the Cre recombinase under diverse promoters such as collagens, glial fibrillary acidic protein (<italic>Gfap</italic>), <italic>Pdgfb</italic> and <italic>Lrat</italic> (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B49">49</xref>&#x2013;<xref ref-type="bibr" rid="B53">53</xref>). Among these, LRAT is expressed selectively in HSCs and not in hepatocytes, cholangiocytes and endothelial cells in the liver. Thus, the <italic>Lrat<sup>Cre</sup>
</italic> deleter mouse has provided a valuable tool for deeper understanding of the physiopathology of liver fibrosis and HCC development (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B54">54</xref>&#x2013;<xref ref-type="bibr" rid="B58">58</xref>). In the current study, we ablated the <italic>Socs1</italic> gene using the <italic>Lrat<sup>Cre</sup>
</italic> deleter to understand the role of SOCS1 in regulating HSC activation. Our findings reveal a non-redundant cell-intrinsic role of SOCS1 in HSCs that controls HSC activation by TGF&#x3b2; and amplification of the hepatic inflammatory response in liver fibrosis (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>).</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Proposed functions of SOCS1 in HSCs. Following hepatocyte damage, quiescent HSCs become activated and differentiate towards myofibroblasts to repair tissue damage. Liver resident and recruit macrophages contribute to HSC activation via secreting TGF&#x3b2;, PDGF, chemokines and inflammatory cytokines. Activated HSCs produce autocrine TGF&#x3b2;, which induces fibrogenic genes that promote synthesis and accumulation of ECM. TGF&#x3b2; also induces autocrine PDGFB that promotes myofibroblast proliferation and induces CCL2 gene expression in HSCs that recruits macrophages and other inflammatory cells. During liver fibrosis, SOCS1 plays a crucial cell-intrinsic regulatory role in HSCs to control TGF&#x3b2;-induced expression of fibrogenic and chemokine genes and autocrine TGF&#x3b2; and PDGFB production.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1259246-g007.tif"/>
</fig>
<p>SOCS1 expression can attenuate several cytokines that signal via the canonical JAK-STAT pathway as well as many growth factors that signal via receptor tyrosine kinases (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B59">59</xref>). Our finding that <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice develop severe fibrosis compared to control mice indicates that SOCS1 regulates cytokines and growth factors that promote HSC activation. PDGFB, which signals via the PDGFR&#x3b1; and PDGFR&#x3b2; receptor tyrosine kinases and activates ERK and AKT signaling pathways, is a potent paracrine and autocrine mitogen for HSCs (<xref ref-type="bibr" rid="B60">60</xref>). Whereas transgenic expression of PDGFB in the liver under albumin promoter increased collagen deposition and promoted CCl<sub>4</sub>-induced liver fibrosis, ablation of PDGFR&#x3b2; in HSCs attenuated liver fibrosis (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B61">61</xref>). SOCS1 was reported to interact with PDGFR (<xref ref-type="bibr" rid="B62">62</xref>). PDGF stimulation of primary HSCs from <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice did not alter the expression of the fibrogenic genes (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>). However, we have shown that primary HSCs from whole body SOCS1 deficient mice display increased proliferation to PDGF stimulation (<xref ref-type="bibr" rid="B26">26</xref>), suggesting a role for SOCS1 in regulating HSC proliferation in liver fibrosis. In support of this notion, we observed increased induction of ERK1/2 phosphorylation in the livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>), suggesting deregulated PDGFR signaling in SOCS1-deficient HSCs. However, further studies using <italic>Socs1<sup>&#x394;HSC</sup>
</italic> primary HSCs are needed to determine potential contribution of other growth factors such as EGF, as it is also mitogenic to HSCs and SOCS1 can attenuate EGFR signaling (<xref ref-type="bibr" rid="B63">63</xref>&#x2013;<xref ref-type="bibr" rid="B65">65</xref>).</p>
<p>Among the cytokines that signal via the JAK-STAT pathway, IL-6 could be involved in liver fibrosis via amplifying the intercellular communication between stressed hepatocytes, HSCs and macrophages (<xref ref-type="bibr" rid="B12">12</xref>). IL-6 was also reported to stimulate the expression of <italic>Acta2</italic> and <italic>Col1a</italic> expression in human HSCs (<xref ref-type="bibr" rid="B66">66</xref>). As SOCS1 was initially discovered as a negative regulator of the inflammatory cytokine IL-6 signaling (<xref ref-type="bibr" rid="B67">67</xref>), loss of SOCS1 could amplify IL-6 signaling and promote liver fibrosis. Earlier studies using whole body <italic>Il6</italic> knockout mice reported an anti-fibrotic role of IL-6 although another study has reported potential pro-fibrotic effects (<xref ref-type="bibr" rid="B68">68</xref>&#x2013;<xref ref-type="bibr" rid="B70">70</xref>). Given that IL-6 is critical for hepatocyte survival and liver regeneration, it was postulated that decreased hepatocyte survival in the absence of IL-6 resulted in sustained hepatocyte damage, contributing to increased fibrosis in Il6-deficient mice rather than a direct anti-fibrotic role of IL-6 (<xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B71">71</xref>). In support of this possibility, we did not observe any significant increase in the induction of fibrogenic genes in primary HSCs from <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice following IL-6 stimulation (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>), possibly because SOCS3, which is a more potent regulator of IL-6 signaling than SOCS1 and is necessary to control IL-6 signaling <italic>in vivo</italic> (<xref ref-type="bibr" rid="B72">72</xref>), is intact in SOCS1-deficient HSCs.</p>
<p>A direct effect of SOCS1 deficiency in HSCs was the elevated expression of the fibrogenic genes <italic>Acta2</italic>, <italic>Col1a1</italic> and <italic>Timp1</italic>, <italic>Pdgfb</italic> coding for PDGFB and autocrine <italic>Tgfb</italic> induction following TGF&#x3b2; stimulation (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>), suggesting deregulated TGF&#x3b2; signaling in SOCS1-deficient HSCs. This idea is supported by increased SMAD3 phosphorylation in the fibrotic livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). SMAD3 is considered more crucial for the pro-fibrogenic effect of TGF&#x3b2; (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>). SOCS1 deficiency might potentiate TGF&#x3b2; signaling in HSCs by multiple mechanisms: In quiescent HSCs, the TGF&#x3b2;-induced canonical SMAD2/3 pathway is attenuated by the TGF&#x3b2; pseudoreceptor BAMBI, which is downmodulated by NF-&#x3ba;B that is activated by lipopolysaccharides (LPS) from the gut microbiota via the toll like receptor 4 (TLR4) (<xref ref-type="bibr" rid="B75">75</xref>). SOCS1 is a key regulator of TLR4 signaling in macrophages (<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>). SOCS1 controls LPS-induced NF-&#x3ba;B signaling by virtue of its ability to function as a substrate adaptor for protein ubiquitination. SOCS1 attenuates TLR4 signaling by promoting ubiquitination and proteasomal degradation of a key signaling adaptor the Toll/Interleukin-1 receptor domain containing adaptor protein (TIRAP, also called MAL) (<xref ref-type="bibr" rid="B78">78</xref>). Besides, SOCS1 promotes ubiquitination-dependent degradation of p65RelA component of NF-&#x3ba;B itself (<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B80">80</xref>). In addition to the canonical SMAD2/SMAD3 signaling pathway, TGF&#x3b2; activates JAK1-STAT3 signaling that synergizes with the SMAD3 pathway (<xref ref-type="bibr" rid="B81">81</xref>). This pathway can potentially be regulated by SOCS1 via inhibition of JAK1. Clearly, further studies are needed to elucidate the mechanistic basis of SOCS1-dependent regulation of TGF&#x3b2; signaling in HSCs.</p>
<p>TGF&#x3b2; stimulation of SOCS1-deficient HSCs increased the induction of <italic>Ccl2</italic>, which is a target gene of NF-&#x3ba;B and encodes MCP-1/CCL2. CCL2 is a key chemoattractant for macrophages, plays a crucial role in liver fibrosis and a potential therapeutic target (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B83">83</xref>). The fibrotic livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice also showed elevated expression of <italic>Ccl2</italic> and increased numbers of macrophages (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). Macrophages play a key role in liver homeostasis (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B84">84</xref>). The normal liver harbors a large reservoir of tissue resident Kupffer cells distributed along the liver sinusoids and monocyte-derived macrophages that are mainly located in the periportal regions. However, hepatic tissue injury causes a large influx of monocyte-derived macrophages that are Ly6C+, express CCR2 and are pro-inflammatory in function. These inflammatory macrophages secrete mediators that attract immune cells, activate HSCs to become myofibroblasts and modulate the ECM, all functions aimed at containing the tissue damage (<xref ref-type="bibr" rid="B13">13</xref>). Subsequently, these inflammatory macrophages transition to restorative macrophages that downregulate Ly6C and CCR2 levels, upregulate the chemokine receptor CX3CR1 expression and help clear the ECM and apoptotic HSCs (<xref ref-type="bibr" rid="B45">45</xref>). Strikingly, macrophages that express CX3CR1 without downmodulating Ly6C or CCR2 (Ly6C<sup>hi</sup>CCR2+CX3CR1+) accumulate in the fibrotic livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>). These cells likely represent intermediate, transitional state cells that would eventually become pro-restorative Ly6C<sup>lo</sup>CCR2&#x2212;CX3CR1+ macrophages upon cessation of the fibrotic stimuli. The fact that these cells are discernibly increased in number in the fibrotic livers of control <italic>Socs1<sup>fl/fl</sup>
</italic> mice suggests that increased inflammatory response in the livers of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice, originating from deregulated cytokine and growth factor signaling in HSCs, hampers this transition. Transcriptomic and proteomic studies on studies on purified HSCs and macrophages from the control and fibrotic livers of <italic>Socs1<sup>fl/fl</sup> Socs1<sup>&#x394;HSC</sup>
</italic> mice and co-culture experiments using purified HSCs and macrophages would be needed to fully understand how SOCS1-HSCs modulate macrophage phenotype and functions.</p>
<p>Inflammation associated with liver fibrosis is a key driver of HCC development and progression (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). Deletion of Lim homeobox domain 2 (<italic>Lhx2</italic>), a repressor of HSC activation, in HSCs was shown to shift these cells from cytokine-producing phenotype towards the persistently myofibroblastic phenotype and promote HCC development (<xref ref-type="bibr" rid="B48">48</xref>). We observed a similarly increased susceptibility of <italic>Socs1<sup>&#x394;HSC</sup>
</italic> mice to liver fibrosis and HCC development. Overall, our findings show that SOCS1 regulates HSC activation by TGF&#x3b2; and thereby controls liver fibrosis and HCC development at least partly via attenuating pro-inflammatory macrophage recruitment and promoting their transition to restorative macrophages.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The animal study was approved by Universit&#xe9; de Sherbrooke Ethics Committee for Animal Care and Use. The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>RK: Formal Analysis, Investigation, Methodology, Writing &#x2013; original draft. MY: Investigation, Methodology, Writing &#x2013; review &amp; editing. AY: Writing &#x2013; review &amp; editing, Resources. AM: Writing &#x2013; review &amp; editing, Funding acquisition, Investigation, Methodology, Supervision. SR: Investigation, Methodology, Writing &#x2013; review &amp; editing, Conceptualization, Formal Analysis, Resources, Validation. SI: Conceptualization, Formal Analysis, Investigation, Methodology, Resources, Validation, Writing &#x2013; review &amp; editing, Data curation, Funding acquisition, Project administration, Supervision, Visualization, Writing &#x2013; original draft.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by a Project grant from the Canadian Institutes of Health Research (CIHR) to SI (PJT-153255).</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>RK was a recipient of a doctoral fellowship from Fonds de Recherche du Qu&#xe9;bec-Sant&#xe9; (FRQS). <xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref> was created with BioRender.</p>
</ack>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2023.1259246/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2023.1259246/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.pdf" id="ST1" mimetype="application/pdf"/>
<supplementary-material xlink:href="DataSheet_1.pdf" id="SM1" mimetype="application/pdf"/>
</sec>
<fn-group>
<title>Abbreviations</title>
<fn fn-type="abbr">
<p>ALT, alanine transferase; CCl<sub>4</sub>, carbon tetrachloride; ECM, extracellular matrix; LF, Liver fibrosis; MMP, matrix metalloproteinase; NDP, nanozoomer Digital Pathology; SOCS, suppressor of cytokine signaling; SMA, smooth muscle actin; TIMP, tissue inhibitor of MMP.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gines</surname> <given-names>P</given-names>
</name>
<name>
<surname>Krag</surname> <given-names>A</given-names>
</name>
<name>
<surname>Abraldes</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Sola</surname> <given-names>E</given-names>
</name>
<name>
<surname>Fabrellas</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kamath</surname> <given-names>PS</given-names>
</name>
</person-group>. <article-title>Liver cirrhosis</article-title>. <source>Lancet</source> (<year>2021</year>) <volume>398</volume>:<page-range>1359&#x2013;76</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(21)01374-X</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Llovet</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Montal</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sia</surname> <given-names>D</given-names>
</name>
<name>
<surname>Finn</surname> <given-names>RS</given-names>
</name>
</person-group>. <article-title>Molecular therapies and precision medicine for hepatocellular carcinoma</article-title>. <source>Nat Rev Clin Oncol</source> (<year>2018</year>) <volume>15</volume>:<fpage>599</fpage>&#x2013;<lpage>616</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41571-018-0073-4</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Llovet</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Kelley</surname> <given-names>RK</given-names>
</name>
<name>
<surname>Villanueva</surname> <given-names>A</given-names>
</name>
<name>
<surname>Singal</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Pikarsky</surname> <given-names>E</given-names>
</name>
<name>
<surname>Roayaie</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Hepatocellular carcinoma</article-title>. <source>Nat Rev Dis Primers</source> (<year>2021</year>) <volume>7</volume>:<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41572-020-00240-3</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bataller</surname> <given-names>R</given-names>
</name>
<name>
<surname>Brenner</surname> <given-names>DA</given-names>
</name>
</person-group>. <article-title>Liver fibrosis</article-title>. <source>J Clin Invest</source> (<year>2005</year>) <volume>115</volume>:<page-range>209&#x2013;18</page-range>. doi: <pub-id pub-id-type="doi">10.1172/JCI24282</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernandez-Gea</surname> <given-names>V</given-names>
</name>
<name>
<surname>Friedman</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Pathogenesis of liver fibrosis</article-title>. <source>Annu Rev Pathol</source> (<year>2011</year>) <volume>6</volume>:<page-range>425&#x2013;56</page-range>. doi: <pub-id pub-id-type="doi">10.1146/annurev-pathol-011110-130246</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiang</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Pritchard</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Nagy</surname> <given-names>LE</given-names>
</name>
</person-group>. <article-title>Obesity, diabetes mellitus, and liver fibrosis</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source> (<year>2011</year>) <volume>300</volume>:<page-range>G697&#x2013;702</page-range>. doi: <pub-id pub-id-type="doi">10.1152/ajpgi.00426.2010</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Mechanisms of hepatic fibrogenesis</article-title>. <source>Gastroenterology</source> (<year>2008</year>) <volume>134</volume>:<page-range>1655&#x2013;69</page-range>. doi: <pub-id pub-id-type="doi">10.1053/j.gastro.2008.03.003</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pellicoro</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ramachandran</surname> <given-names>P</given-names>
</name>
<name>
<surname>Iredale</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Fallowfield</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>Liver fibrosis and repair: immune regulation of wound healing in a solid organ</article-title>. <source>Nat Rev Immunol</source> (<year>2014</year>) <volume>14</volume>:<page-range>181&#x2013;94</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri3623</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farazi</surname> <given-names>PA</given-names>
</name>
<name>
<surname>DePinho</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Hepatocellular carcinoma pathogenesis: from genes to environment</article-title>. <source>Nat Rev Cancer</source> (<year>2006</year>) <volume>6</volume>:<page-range>674&#x2013;87</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrc1934</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>DY</given-names>
</name>
<name>
<surname>Friedman</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Fibrosis-dependent mechanisms of hepatocarcinogenesis</article-title>. <source>Hepatology</source> (<year>2012</year>) <volume>56</volume>:<page-range>769&#x2013;75</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.25670</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>YA</given-names>
</name>
<name>
<surname>Wallace</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Friedman</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Pathobiology of liver fibrosis: a translational success story</article-title>. <source>Gut</source> (<year>2015</year>) <volume>64</volume>:<page-range>830&#x2013;41</page-range>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2014-306842</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trautwein</surname> <given-names>C</given-names>
</name>
<name>
<surname>Friedman</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Schuppan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Pinzani</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Hepatic fibrosis: Concept to treatment</article-title>. <source>J Hepatol</source> (<year>2015</year>) <volume>62</volume>:<page-range>S15&#x2013;24</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2015.02.039</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tacke</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Targeting hepatic macrophages to treat liver diseases</article-title>. <source>J Hepatol</source> (<year>2017</year>) <volume>66</volume>:<page-range>1300&#x2013;12</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2017.02.026</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsuchida</surname> <given-names>T</given-names>
</name>
<name>
<surname>Friedman</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Mechanisms of hepatic stellate cell activation</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> (<year>2017</year>) <volume>14</volume>:<fpage>397</fpage>&#x2013;<lpage>411</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrgastro.2017.38</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liedtke</surname> <given-names>C</given-names>
</name>
<name>
<surname>Luedde</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sauerbruch</surname> <given-names>T</given-names>
</name>
<name>
<surname>Scholten</surname> <given-names>D</given-names>
</name>
<name>
<surname>Streetz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Tacke</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Experimental liver fibrosis research: update on animal models, legal issues and translational aspects</article-title>. <source>Fibrogenesis Tissue Repair</source> (<year>2013</year>) <volume>6</volume>:<fpage>19</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1755-1536-6-19</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delire</surname> <given-names>B</given-names>
</name>
<name>
<surname>Starkel</surname> <given-names>P</given-names>
</name>
<name>
<surname>Leclercq</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Animal models for fibrotic liver diseases: what we have, what we need, and what is under development</article-title>. <source>J Clin Transl Hepatol</source> (<year>2015</year>) <volume>3</volume>:<fpage>53</fpage>&#x2013;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.14218/JCTH.2014.00035</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bao</surname> <given-names>YL</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>HT</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>TR</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>SJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Animal and organoid models of liver fibrosis</article-title>. <source>Front Physiol</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>666138</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2021.666138</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname> <given-names>SL</given-names>
</name>
</person-group>. <article-title>Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver</article-title>. <source>Physiol Rev</source> (<year>2008</year>) <volume>88</volume>:<page-range>125&#x2013;72</page-range>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00013.2007</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seki</surname> <given-names>E</given-names>
</name>
<name>
<surname>Schwabe</surname> <given-names>RF</given-names>
</name>
</person-group>. <article-title>Hepatic inflammation and fibrosis: functional links and key pathways</article-title>. <source>Hepatology</source> (<year>2015</year>) <volume>61</volume>:<page-range>1066&#x2013;79</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.27332</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higashi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Friedman</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Hoshida</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Hepatic stellate cells as key target in liver fibrosis</article-title>. <source>Adv Drug Deliv Rev</source> (<year>2017</year>) <volume>121</volume>:<fpage>27</fpage>&#x2013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.addr.2017.05.007</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshimura</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ito</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chikuma</surname> <given-names>S</given-names>
</name>
<name>
<surname>Akanuma</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nakatsukasa</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Negative regulation of cytokine signaling in immunity</article-title>. <source>Cold Spring Harb Perspect Biol</source> (<year>2018</year>) <volume>10</volume>(<issue>7</issue>):<elocation-id>a028571</elocation-id>. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a028571</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alexander</surname> <given-names>WS</given-names>
</name>
</person-group>. <article-title>Suppressors of cytokine signalling (SOCS) in the immune system</article-title>. <source>Nat Rev Immunol</source> (<year>2002</year>) <volume>2</volume>:<page-range>410&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri818</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kazi</surname> <given-names>JU</given-names>
</name>
<name>
<surname>Kabir</surname> <given-names>NN</given-names>
</name>
<name>
<surname>Flores-Morales</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ronnstrand</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>SOCS proteins in regulation of receptor tyrosine kinase signaling</article-title>. <source>Cell Mol Life Sci: CMLS</source> (<year>2014</year>) <volume>71</volume>:<page-range>3297&#x2013;310</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00018-014-1619-y</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sachithanandan</surname> <given-names>N</given-names>
</name>
<name>
<surname>Graham</surname> <given-names>KL</given-names>
</name>
<name>
<surname>Galic</surname> <given-names>S</given-names>
</name>
<name>
<surname>Honeyman</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Fynch</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Hewitt</surname> <given-names>KA</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage deletion of SOCS1 increases sensitivity to LPS and palmitic acid and results in systemic inflammation and hepatic insulin resistance</article-title>. <source>Diabetes</source> (<year>2011</year>) <volume>60</volume>:<page-range>2023&#x2013;31</page-range>. doi: <pub-id pub-id-type="doi">10.2337/db11-0259</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname> <given-names>T</given-names>
</name>
<name>
<surname>Ogata</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kamio</surname> <given-names>M</given-names>
</name>
<name>
<surname>Joo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Shiraishi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Tokunaga</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>199</volume>:<page-range>1701&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20031675</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kandhi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bobbala</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yeganeh</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mayhue</surname> <given-names>M</given-names>
</name>
<name>
<surname>Menendez</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ilangumaran</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Negative regulation of the hepatic fibrogenic response by suppressor of cytokine signaling 1</article-title>. <source>Cytokine</source> (<year>2016</year>) <volume>82</volume>:<fpage>58</fpage>&#x2013;<lpage>69</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cyto.2015.12.007</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mafanda</surname> <given-names>EK</given-names>
</name>
<name>
<surname>Kandhi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bobbala</surname> <given-names>D</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>MGM</given-names>
</name>
<name>
<surname>Nandi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Menendez</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Essential role of suppressor of cytokine signaling 1 (SOCS1) in hepatocytes and macrophages in the regulation of liver fibrosis</article-title>. <source>Cytokine</source> (<year>2019</year>) <volume>124</volume>:<fpage>154501</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cyto.2018.07.032</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mederacke</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hsu</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Troeger</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Huebener</surname> <given-names>P</given-names>
</name>
<name>
<surname>Mu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Dapito</surname> <given-names>DH</given-names>
</name>
<etal/>
</person-group>. <article-title>Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology</article-title>. <source>Nat Commun</source> (<year>2013</year>) <volume>4</volume>:<fpage>2823</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms3823</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>&#xd6;sterreicher</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Lemberger</surname> <given-names>UJ</given-names>
</name>
<name>
<surname>Mahon</surname> <given-names>R</given-names>
</name>
<name>
<surname>R&#xfc;licke</surname> <given-names>T</given-names>
</name>
<name>
<surname>Trauner</surname> <given-names>M</given-names>
</name>
<name>
<surname>Casanova</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>O147 Hepatic Stellate cells are the major source of collagen in murine models of liver fibrosis</article-title>. <source>J Hepatol</source> (<year>2014</year>) <volume>60</volume>:<fpage>S61</fpage>.</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanaka</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ichiyama</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hashimoto</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yoshida</surname> <given-names>H</given-names>
</name>
<name>
<surname>Takimoto</surname> <given-names>T</given-names>
</name>
<name>
<surname>Takaesu</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>180</volume>:<page-range>3746&#x2013;56</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.180.6.3746</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madisen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zwingman</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Sunkin</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Oh</surname> <given-names>SW</given-names>
</name>
<name>
<surname>Zariwala</surname> <given-names>HA</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>A robust and high-throughput Cre reporting and characterization system for the whole mouse brain</article-title>. <source>Nat Neurosci</source> (<year>2010</year>) <volume>13</volume>:<page-range>133&#x2013;40</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nn.2467</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scholten</surname> <given-names>D</given-names>
</name>
<name>
<surname>Trebicka</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liedtke</surname> <given-names>C</given-names>
</name>
<name>
<surname>Weiskirchen</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>The carbon tetrachloride model in mice</article-title>. <source>Lab Anim</source> (<year>2015</year>) <volume>49</volume>:<fpage>4</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0023677215571192</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naugler</surname> <given-names>WE</given-names>
</name>
<name>
<surname>Sakurai</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>S</given-names>
</name>
<name>
<surname>Maeda</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>K</given-names>
</name>
<name>
<surname>Elsharkawy</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production</article-title>. <source>Science</source> (<year>2007</year>) <volume>317</volume>:<page-range>121&#x2013;4</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.1140485</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimizu</surname> <given-names>I</given-names>
</name>
<name>
<surname>Ito</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Protection of estrogens against the progression of chronic liver disease</article-title>. <source>Hepatol Res</source> (<year>2007</year>) <volume>37</volume>:<page-range>239&#x2013;47</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1872-034X.2007.00032.x</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romualdo</surname> <given-names>GR</given-names>
</name>
<name>
<surname>Prata</surname> <given-names>GB</given-names>
</name>
<name>
<surname>da Silva</surname> <given-names>TC</given-names>
</name>
<name>
<surname>Fernandes</surname> <given-names>AAH</given-names>
</name>
<name>
<surname>Moreno</surname> <given-names>FS</given-names>
</name>
<name>
<surname>Cogliati</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Fibrosis-associated hepatocarcinogenesis revisited: Establishing standard medium-term chemically-induced male and female models</article-title>. <source>PloS One</source> (<year>2018</year>) <volume>13</volume>:<elocation-id>e0203879</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0203879</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Song</surname> <given-names>L</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Isolation and culture of hepatic stellate cells from mouse liver</article-title>. <source>Acta Biochim Biophys Sin (Shanghai)</source> (<year>2014</year>) <volume>46</volume>:<page-range>291&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1093/abbs/gmt143</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mederacke</surname> <given-names>I</given-names>
</name>
<name>
<surname>Dapito</surname> <given-names>DH</given-names>
</name>
<name>
<surname>Affo</surname> <given-names>S</given-names>
</name>
<name>
<surname>UChinami</surname> <given-names>H</given-names>
</name>
<name>
<surname>Schwabe</surname> <given-names>RF</given-names>
</name>
</person-group>. <article-title>High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers</article-title>. <source>Nat Protoc</source> (<year>2015</year>) <volume>10</volume>:<page-range>305&#x2013;15</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nprot.2015.017</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kandhi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Variya</surname> <given-names>B</given-names>
</name>
<name>
<surname>Ramanathan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ilangumaran</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>An improved method for isolation and flow cytometric characterization of intrahepatic leukocytes from fatty and fibrotic liver tissues</article-title>. <source>Anat Rec (Hoboken)</source> (<year>2022</year>) <volume>306</volume>(<issue>5</issue>):<page-range>1011&#x2013;30</page-range>. doi: <pub-id pub-id-type="doi">10.1002/ar.25039</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uehara</surname> <given-names>T</given-names>
</name>
<name>
<surname>Pogribny</surname> <given-names>IP</given-names>
</name>
<name>
<surname>Rusyn</surname> <given-names>I</given-names>
</name>
<name>
<surname>The</surname> <given-names>DEN</given-names>
</name>
</person-group>. <article-title>and CCl4 -induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma</article-title>. <source>Curr Protoc Pharmacol</source> (<year>2014</year>) <volume>66</volume>:<fpage>14 30 1</fpage>&#x2013;<lpage>14 30 10</lpage>. doi: <pub-id pub-id-type="doi">10.1002/0471141755.ph1430s66</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname> <given-names>MGM</given-names>
</name>
<name>
<surname>Ghosh</surname> <given-names>A</given-names>
</name>
<name>
<surname>Variya</surname> <given-names>B</given-names>
</name>
<name>
<surname>Santharam</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Kandhi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ramanathan</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Hepatocyte growth control by SOCS1 and SOCS3</article-title>. <source>Cytokine</source> (<year>2019</year>) <volume>121</volume>:<fpage>154733</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cyto.2019.154733</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannandrea</surname> <given-names>M</given-names>
</name>
<name>
<surname>Parks</surname> <given-names>WC</given-names>
</name>
</person-group>. <article-title>Diverse functions of matrix metalloproteinases during fibrosis</article-title>. <source>Dis Model Mech</source> (<year>2014</year>) <volume>7</volume>:<fpage>193</fpage>&#x2013;<lpage>203</lpage>. doi: <pub-id pub-id-type="doi">10.1242/dmm.012062</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname> <given-names>J</given-names>
</name>
<name>
<surname>Roulot</surname> <given-names>D</given-names>
</name>
<name>
<surname>Koteliansky</surname> <given-names>VE</given-names>
</name>
<name>
<surname>Bissell</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>
<italic>In vivo</italic> inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>1999</year>) <volume>96</volume>:<page-range>12719&#x2013;24</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.96.22.12719</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dewidar</surname> <given-names>B</given-names>
</name>
<name>
<surname>Meyer</surname> <given-names>C</given-names>
</name>
<name>
<surname>Dooley</surname> <given-names>S</given-names>
</name>
<name>
<surname>Meindl-Beinker</surname> <given-names>AN</given-names>
</name>
</person-group>. <article-title>TGF-beta in hepatic stellate cell activation and liver fibrogenesis-updated 2019</article-title>. <source>Cells</source> (<year>2019</year>) <volume>8</volume>(<issue>11</issue>):<fpage>1419</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells8111419</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Czochra</surname> <given-names>P</given-names>
</name>
<name>
<surname>Klopcic</surname> <given-names>B</given-names>
</name>
<name>
<surname>Meyer</surname> <given-names>E</given-names>
</name>
<name>
<surname>Herkel</surname> <given-names>J</given-names>
</name>
<name>
<surname>Garcia-Lazaro</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Thieringer</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice</article-title>. <source>J Hepatol</source> (<year>2006</year>) <volume>45</volume>:<page-range>419&#x2013;28</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2006.04.010</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krenkel</surname> <given-names>O</given-names>
</name>
<name>
<surname>Tacke</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Liver macrophages in tissue homeostasis and disease</article-title>. <source>Nat Rev Immunol</source> (<year>2017</year>) <volume>17</volume>:<page-range>306&#x2013;21</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri.2017.11</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geissmann</surname> <given-names>F</given-names>
</name>
<name>
<surname>Jung</surname> <given-names>S</given-names>
</name>
<name>
<surname>Littman</surname> <given-names>DR</given-names>
</name>
</person-group>. <article-title>Blood monocytes consist of two principal subsets with distinct migratory properties</article-title>. <source>Immunity</source> (<year>2003</year>) <volume>19</volume>:<fpage>71</fpage>&#x2013;<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1074-7613(03)00174-2</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname> <given-names>AI</given-names>
</name>
<name>
<surname>Conroy</surname> <given-names>KP</given-names>
</name>
<name>
<surname>Henderson</surname> <given-names>NC</given-names>
</name>
</person-group>. <article-title>Hepatic stellate cells: central modulators of hepatic carcinogenesis</article-title>. <source>BMC Gastroenterol</source> (<year>2015</year>) <volume>15</volume>:<fpage>63</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12876-015-0291-5</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filliol</surname> <given-names>A</given-names>
</name>
<name>
<surname>Saito</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Nair</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dapito</surname> <given-names>DH</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>LX</given-names>
</name>
<name>
<surname>Ravichandra</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis</article-title>. <source>Nature</source> (<year>2022</year>) <volume>610</volume>:<page-range>356&#x2013;65</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41586-022-05289-6</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Jung</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Omenetti</surname> <given-names>A</given-names>
</name>
<name>
<surname>Witek</surname> <given-names>RP</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Vandongen</surname> <given-names>HM</given-names>
</name>
<etal/>
</person-group>. <article-title>Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers</article-title>. <source>Stem Cells</source> (<year>2008</year>) <volume>26</volume>:<page-range>2104&#x2013;13</page-range>. doi: <pub-id pub-id-type="doi">10.1634/stemcells.2008-0115</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kisseleva</surname> <given-names>T</given-names>
</name>
<name>
<surname>Cong</surname> <given-names>M</given-names>
</name>
<name>
<surname>Paik</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Scholten</surname> <given-names>D</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Benner</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis</article-title>. <source>Proc Natl Acad Sci United States America</source> (<year>2012</year>) <volume>109</volume>:<page-range>9448&#x2013;53</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1201840109</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lujambio</surname> <given-names>A</given-names>
</name>
<name>
<surname>Akkari</surname> <given-names>L</given-names>
</name>
<name>
<surname>Simon</surname> <given-names>J</given-names>
</name>
<name>
<surname>Grace</surname> <given-names>D</given-names>
</name>
<name>
<surname>Tschaharganeh</surname> <given-names>DF</given-names>
</name>
<name>
<surname>Bolden</surname> <given-names>JE</given-names>
</name>
<etal/>
</person-group>. <article-title>Non-cell-autonomous tumor suppression by p53</article-title>. <source>Cell</source> (<year>2013</year>) <volume>153</volume>:<page-range>449&#x2013;60</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2013.03.020</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henderson</surname> <given-names>NC</given-names>
</name>
<name>
<surname>Arnold</surname> <given-names>TD</given-names>
</name>
<name>
<surname>Katamura</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Giacomini</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Rodriguez</surname> <given-names>JD</given-names>
</name>
<name>
<surname>McCarty</surname> <given-names>JH</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs</article-title>. <source>Nat Med</source> (<year>2013</year>) <volume>19</volume>:<page-range>1617&#x2013;24</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm.3282</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenhalgh</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Conroy</surname> <given-names>KP</given-names>
</name>
<name>
<surname>Henderson</surname> <given-names>NC</given-names>
</name>
</person-group>. <article-title>Cre-ativity in the liver: transgenic approaches to targeting hepatic nonparenchymal cells</article-title>. <source>Hepatology</source> (<year>2015</year>) <volume>61</volume>:<page-range>2091&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.27606</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kikuchi</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Nakao</surname> <given-names>T</given-names>
</name>
<name>
<surname>Russell</surname> <given-names>JO</given-names>
</name>
<name>
<surname>Preziosi</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Poddar</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Elimination of wnt secretion from stellate cells is dispensable for zonation and development of liver fibrosis following hepatobiliary injury</article-title>. <source>Gene Expr</source> (<year>2019</year>) <volume>19</volume>:<page-range>121&#x2013;36</page-range>. doi: <pub-id pub-id-type="doi">10.3727/105221618X15373858350141</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poole</surname> <given-names>LG</given-names>
</name>
<name>
<surname>Pant</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cline-Fedewa</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Copple</surname> <given-names>BL</given-names>
</name>
<name>
<surname>Palumbo</surname> <given-names>JS</given-names>
</name>
<etal/>
</person-group>. <article-title>Liver fibrosis is driven by protease-activated receptor-1 expressed by hepatic stellate cells in experimental chronic liver injury</article-title>. <source>Res Pract Thromb Haemost</source> (<year>2020</year>) <volume>4</volume>:<page-range>906&#x2013;17</page-range>. doi: <pub-id pub-id-type="doi">10.1002/rth2.12403</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Rosenthal</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>McCubbin</surname> <given-names>R</given-names>
</name>
<name>
<surname>Meshgin</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution</article-title>. <source>Gastroenterology</source> (<year>2020</year>) <volume>158</volume>:<fpage>1728</fpage>&#x2013;<lpage>1744 e14</lpage>. doi: <pub-id pub-id-type="doi">10.1053/j.gastro.2020.01.027</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamberger</surname> <given-names>F</given-names>
</name>
<name>
<surname>Mederacke</surname> <given-names>YS</given-names>
</name>
<name>
<surname>Mederacke</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>An inducible model for genetic manipulation and fate-tracing of PDGFRbeta-expressing fibrogenic cells in the liver</article-title>. <source>Sci Rep</source> (<year>2023</year>) <volume>13</volume>:<fpage>7322</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-023-34353-y</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Min</surname> <given-names>K</given-names>
</name>
<name>
<surname>Yenilmez</surname> <given-names>B</given-names>
</name>
<name>
<surname>Kelly</surname> <given-names>M</given-names>
</name>
<name>
<surname>Echeverria</surname> <given-names>D</given-names>
</name>
<name>
<surname>Elleby</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lifshitz</surname> <given-names>LM</given-names>
</name>
<etal/>
</person-group>. <article-title>Lactate transporter MCT1 in hepatic stellate cells promotes fibrotic collagen expression in nonalcoholic steatohepatitis</article-title>. <source>bioRxiv</source> (<year>2023</year>). doi: <pub-id pub-id-type="doi">10.1101/2023.05.03.539244</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trengove</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Ward</surname> <given-names>AC</given-names>
</name>
</person-group>. <article-title>SOCS proteins in development and disease</article-title>. <source>Am J Clin Exp Immunol</source> (<year>2013</year>) <volume>2</volume>:<fpage>1</fpage>&#x2013;<lpage>29</lpage>.</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonner</surname> <given-names>JC</given-names>
</name>
</person-group>. <article-title>Regulation of PDGF and its receptors in fibrotic diseases</article-title>. <source>Cytokine Growth Factor Rev</source> (<year>2004</year>) <volume>15</volume>:<page-range>255&#x2013;73</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cytogfr.2004.03.006</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kocabayoglu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lade</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>YA</given-names>
</name>
<name>
<surname>Dragomir</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>X</given-names>
</name>
<name>
<surname>Fiel</surname> <given-names>MI</given-names>
</name>
<etal/>
</person-group>. <article-title>beta-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis</article-title>. <source>J Hepatol</source> (<year>2015</year>) <volume>63</volume>:<page-range>141&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2015.01.036</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Sepulveda</surname> <given-names>P</given-names>
</name>
<name>
<surname>Okkenhaug</surname> <given-names>K</given-names>
</name>
<name>
<surname>Rose</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Hawley</surname> <given-names>RG</given-names>
</name>
<name>
<surname>Dubreuil</surname> <given-names>P</given-names>
</name>
<name>
<surname>Rottapel</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Socs1 binds to multiple signalling proteins and suppresses steel factor- dependent proliferation</article-title>. <source>EMBO J</source> (<year>1999</year>) <volume>18</volume>:<page-range>904&#x2013;15</page-range>. doi: <pub-id pub-id-type="doi">10.1093/emboj/18.4.904</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuchs</surname> <given-names>BC</given-names>
</name>
<name>
<surname>Hoshida</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fujii</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yamada</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lauwers</surname> <given-names>GY</given-names>
</name>
<etal/>
</person-group>. <article-title>Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma</article-title>. <source>Hepatology</source> (<year>2014</year>) <volume>59</volume>:<page-range>1577&#x2013;90</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.26898</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease</article-title>. <source>Biochim Biophys Acta Mol Basis Dis</source> (<year>2018</year>) <volume>1864</volume>:<page-range>133&#x2013;42</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.bbadis.2017.10.016</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Ivanov</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Ling</surname> <given-names>MY</given-names>
</name>
<name>
<surname>Dragoi</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation</article-title>. <source>J Biol Chem</source> (<year>2002</year>) <volume>277</volume>:<page-range>30716&#x2013;23</page-range>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M202823200</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kagan</surname> <given-names>P</given-names>
</name>
<name>
<surname>Sultan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tachlytski</surname> <given-names>I</given-names>
</name>
<name>
<surname>Safran</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ben-Ari</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Both</surname> <given-names>MAPK</given-names>
</name>
</person-group>. <article-title>and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation</article-title>. <source>PloS One</source> (<year>2017</year>) <volume>12</volume>:<elocation-id>e0176173</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0176173</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname> <given-names>R</given-names>
</name>
<name>
<surname>Willson</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Viney</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Murray</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>Rayner</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Jenkins</surname> <given-names>BJ</given-names>
</name>
<etal/>
</person-group>. <article-title>A family of cytokine-inducible inhibitors of signalling</article-title>. <source>Nature</source> (<year>1997</year>) <volume>387</volume>:<page-range>917&#x2013;21</page-range>. doi: <pub-id pub-id-type="doi">10.1038/43206</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Natsume</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tsuji</surname> <given-names>H</given-names>
</name>
<name>
<surname>Harada</surname> <given-names>A</given-names>
</name>
<name>
<surname>Akiyama</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yano</surname> <given-names>T</given-names>
</name>
<name>
<surname>Ishikura</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Attenuated liver fibrosis and depressed serum albumin levels in carbon tetrachloride-treated IL-6-deficient mice</article-title>. <source>J Leukoc Biol</source> (<year>1999</year>) <volume>66</volume>:<page-range>601&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jlb.66.4.601</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bansal</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Kovalovich</surname> <given-names>K</given-names>
</name>
<name>
<surname>Gupta</surname> <given-names>R</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<name>
<surname>Agarwal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Radbill</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression</article-title>. <source>J Hepatol</source> (<year>2005</year>) <volume>42</volume>:<page-range>548&#x2013;56</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2004.11.043</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovalovich</surname> <given-names>K</given-names>
</name>
<name>
<surname>DeAngelis</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Li</surname> <given-names>W</given-names>
</name>
<name>
<surname>Furth</surname> <given-names>EE</given-names>
</name>
<name>
<surname>Ciliberto</surname> <given-names>G</given-names>
</name>
<name>
<surname>Taub</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice</article-title>. <source>Hepatology</source> (<year>2000</year>) <volume>31</volume>:<page-range>149&#x2013;59</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.510310123</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cressman</surname> <given-names>DE</given-names>
</name>
<name>
<surname>Greenbaum</surname> <given-names>LE</given-names>
</name>
<name>
<surname>DeAngelis</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Ciliberto</surname> <given-names>G</given-names>
</name>
<name>
<surname>Furth</surname> <given-names>EE</given-names>
</name>
<name>
<surname>Poli</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice</article-title>. <source>Science</source> (<year>1996</year>) <volume>274</volume>:<page-range>1379&#x2013;83</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.274.5291.1379</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croker</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Krebs</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Wormald</surname> <given-names>S</given-names>
</name>
<name>
<surname>Willson</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Stanley</surname> <given-names>EG</given-names>
</name>
<etal/>
</person-group>. <article-title>SOCS3 negatively regulates IL-6 signaling in vivo</article-title>. <source>Nat Immunol</source> (<year>2003</year>) <volume>4</volume>:<page-range>540&#x2013;5</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni931</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uemura</surname> <given-names>M</given-names>
</name>
<name>
<surname>Swenson</surname> <given-names>ES</given-names>
</name>
<name>
<surname>Gaca</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Giordano</surname> <given-names>FJ</given-names>
</name>
<name>
<surname>Reiss</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wells</surname> <given-names>RG</given-names>
</name>
</person-group>. <article-title>Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization</article-title>. <source>Mol Biol Cell</source> (<year>2005</year>) <volume>16</volume>:<page-range>4214&#x2013;24</page-range>. doi: <pub-id pub-id-type="doi">10.1091/mbc.e05-02-0149</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>XM</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Smad2 protects against TGF-beta1/Smad3-mediated collagen synthesis in human hepatic stellate cells during hepatic fibrosis</article-title>. <source>Mol Cell Biochem</source> (<year>2015</year>) <volume>400</volume>:<fpage>17</fpage>&#x2013;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11010-014-2258-1</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seki</surname> <given-names>E</given-names>
</name>
<name>
<surname>De Minicis</surname> <given-names>S</given-names>
</name>
<name>
<surname>Osterreicher</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Kluwe</surname> <given-names>J</given-names>
</name>
<name>
<surname>Osawa</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Brenner</surname> <given-names>DA</given-names>
</name>
<etal/>
</person-group>. <article-title>TLR4 enhances TGF-beta signaling and hepatic fibrosis</article-title>. <source>Nat Med</source> (<year>2007</year>) <volume>13</volume>:<page-range>1324&#x2013;32</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm1663</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kinjyo</surname> <given-names>I</given-names>
</name>
<name>
<surname>Hanada</surname> <given-names>T</given-names>
</name>
<name>
<surname>Inagaki-Ohara</surname> <given-names>K</given-names>
</name>
<name>
<surname>Mori</surname> <given-names>H</given-names>
</name>
<name>
<surname>Aki</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ohishi</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>SOCS1/JAB is a negative regulator of LPS-induced macrophage activation</article-title>. <source>Immunity</source> (<year>2002</year>) <volume>17</volume>:<page-range>583&#x2013;91</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1074-7613(02)00446-6</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakagawa</surname> <given-names>R</given-names>
</name>
<name>
<surname>Naka</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tsutsui</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fujimoto</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kimura</surname> <given-names>A</given-names>
</name>
<name>
<surname>Abe</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>SOCS-1 participates in negative regulation of LPS responses</article-title>. <source>Immunity</source> (<year>2002</year>) <volume>17</volume>:<page-range>677&#x2013;87</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1074-7613(02)00449-1</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mansell</surname> <given-names>A</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>R</given-names>
</name>
<name>
<surname>Doyle</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Gray</surname> <given-names>P</given-names>
</name>
<name>
<surname>Fenner</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Crack</surname> <given-names>PJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation</article-title>. <source>Nat Immunol</source> (<year>2006</year>) <volume>7</volume>:<page-range>148&#x2013;55</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni1299</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Suizu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Yoshida</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Perrem</surname> <given-names>K</given-names>
</name>
<name>
<surname>Liou</surname> <given-names>YC</given-names>
</name>
<name>
<surname>Wulf</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA</article-title>. <source>Mol Cell</source> (<year>2003</year>) <volume>12</volume>:<page-range>1413&#x2013;26</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1097-2765(03)00490-8</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strebovsky</surname> <given-names>J</given-names>
</name>
<name>
<surname>Walker</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Dalpke</surname> <given-names>AH</given-names>
</name>
</person-group>. <article-title>Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus</article-title>. <source>FASEB J</source> (<year>2011</year>) <volume>25</volume>:<page-range>863&#x2013;74</page-range>. doi: <pub-id pub-id-type="doi">10.1096/fj.10-170597</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>LY</given-names>
</name>
<name>
<surname>Heller</surname> <given-names>M</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>LR</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Transforming growth factor-beta (TGF-beta) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway</article-title>. <source>J Biol Chem</source> (<year>2017</year>) <volume>292</volume>:<page-range>4302&#x2013;12</page-range>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M116.773085</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seki</surname> <given-names>E</given-names>
</name>
<name>
<surname>de Minicis</surname> <given-names>S</given-names>
</name>
<name>
<surname>Inokuchi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Taura</surname> <given-names>K</given-names>
</name>
<name>
<surname>Miyai</surname> <given-names>K</given-names>
</name>
<name>
<surname>van Rooijen</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>CCR2 promotes hepatic fibrosis in mice</article-title>. <source>Hepatology</source> (<year>2009</year>) <volume>50</volume>:<page-range>185&#x2013;97</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.22952</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehling</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bartneck</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>X</given-names>
</name>
<name>
<surname>Gremse</surname> <given-names>F</given-names>
</name>
<name>
<surname>Fech</surname> <given-names>V</given-names>
</name>
<name>
<surname>Mockel</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis</article-title>. <source>Gut</source> (<year>2014</year>) <volume>63</volume>:<page-range>1960&#x2013;71</page-range>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2013-306294</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ju</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Hepatic macrophages in liver injury</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>322</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.00322</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>